Collaborators will search for heart receptors involved in stem cell trafficking.
CellCyte Genetics signed a collaborative research agreement with physician scientists at the Cleveland Clinic Foundation. The goal is to investigate the presence and regulation of heart receptors involved in stem cell trafficking in normal and diseased human hearts using CellCyte’s compounds.
The Cleveland Clinic Foundation scientists will analyze heart tissue samples of heart failure patients for the presence of surface receptors that are hypothesized to play an important role in the interaction of stem cells with the heart. These studies are expected to provide new information that will increase the understanding of cardiac regeneration and support the discovery and development of stem cell therapeutics for the heart.
CellCyte points out is developing stem cell enabling therapeutic products designed to allow more efficient delivery and significantly increased retention of adult stem cells to diseased organs such as the heart.
The aim of such therapy is to increase the number of stem cells delivered to a damaged organ, thereby increasing organ healing and functional restoration. The company’s first product in development, CCG-TH30, is designed to send autologous bone-marrow-derived stem cells to the heart of patients after a heart attack.